Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.
|Original language||English (US)|
|Title of host publication||Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||12|
|ISBN (Print)||9781634832892, 9781634832731|
|State||Published - Jul 1 2015|
ASJC Scopus subject areas